Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
- 1 November 2003
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 82 (1) , 23-28
- https://doi.org/10.1023/b:brea.0000003916.39959.73
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heartThe Journal of Heart and Lung Transplantation, 2002
- ErbB2 is essential in the prevention of dilated cardiomyopathyNature Medicine, 2002
- Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heartSeminars in Oncology, 2001
- Trastuzumab therapy and the heart: palliation at what cost?Congestive Heart Failure, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Trastuzumab in the Treatment of Metastatic Breast CancerCirculation, 2000
- Neuregulin in Cardiac Hypertrophy in Rats With Aortic StenosisCirculation, 1999
- Biological Response to ErbB Ligands in Nontransformed Cell Lines Correlates with a Specific Pattern of Receptor ExpressionEndocrinology, 1998
- neu tack on neuregulinNature, 1995
- Requirement for neuregulin receptor erbB2 in neural and cardiac developmentNature, 1995